TP53 and pelvic organ prolapse: This study hypothesized that the application of low-dose non-thermal biocompatible plasma (NBP) to human disease (pelvic organ prolapse) would inhibit continuous apoptotic behaviors through blocking the p53 mechanism, which is the world’s first attempt.